 This study will evaluate the drug telbivudine LdT for treatment of hepatitis B virus HBV in HIV infected patients. Patients will take telbivudine alone for 24 weeks, add anti-HIV drugs for 24 weeks, then stop taking telbivudine while continuing their anti-HIV drug regimen. To enroll in this study, patients must not be taking any anti-HIV drugs and cannot have taken more than 31 days of treatment with lamivudine 3TC, protease inhibitors PIs, or nonnucleoside reverse transcriptase inhibitors NNRTIs. 